Real-world multi-omic characterization of small cell lung cancer subtypes reveals differential expression of clinically relevant biomarkers


Sonam Puri, Abdul Rafeh Naqash, Andrew Elliott, Kathleen Claire Kerrigan, Shiven B. Patel, Andreas Seeber, Florian Kocher, DIPESH UPRETY, Hirva Mamdani, Amit Kulkarni, Gilberto Lopes, Balazs Halmos, Hossein Borghaei, Wallace L. Akerley, Stephen V. Liu, Wolfgang Michael Korn, Trudy G Oliver, Taofeek K. Owonikoko

Background: The dominant expression of four lineage-defining transcription factors (ASCL1NEUROD1YAP1, or POU2F3) has enabled the classification of small cell lung cancer (SCLC) into four subtypes (SCLC-A/N/Y/P, respectively). Emerging evidence suggests that YAP1 expression is associated with a T-cell inflamed phenotype, and SCLC has significant intra-tumor heterogeneity mediated by MYC-driven activation of NOTCH signaling. We performed a large-scale analysis of real-world SCLC patient samples to examine the expression of clinically relevant biomarkers across SCLC subtypes.

Download Publication